Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPATROPHY: Empagliflozin vs glimepiride effects on left ventricular mass in type 2 diabetes
2014-003313-28Phase 4Terminated
- Sponsor
- Hannover Medical School
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in type 2 diabetes mellitus (T2DM) and left ventricular hypertrophy (LVH) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Change in left ventricular mass by cardiac MRI. Started Jun 2015; status: terminated.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2014-003313-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003313-28.